You are now leaving

Please click 'Continue to external site' if you want to continue.

Late Phase Development


Anamorelin is a novel, orally available, selective ghrelin receptor agonist that mimics the appetite-enhancing and anabolic effects of the ghrelin hormone.

Development status:

  • Approved in Japan
  • Phase III  global clinical studies (SCALA) completed